Toggle Summary |
Onconova Therapeutics, Inc. to Present at the Cowen and Company 34th Annual Health Care Conference
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Announces Timing for Fourth Quarter and Year-End 2013 Financial Results and Conference Call
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Reports Fourth Quarter and Year-End 2013 Financial Results and Outlines Key Objectives for 2014
|
View HTML
|
Toggle Summary |
Onconova Development Programs Highlighted in Seven Presentations at AACR Annual Meeting
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Announces Timing for First Quarter 2014 Financial Results and Conference Call
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Reports First Quarter 2014 Financial and Operational Results
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2014 Financial Results and Conference Call
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Reports Second Quarter 2014 Financial and Operational Results
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
|
View HTML
|
Toggle Summary |
Onconova Announces Ten Presentations at the 2014 ASH Annual Meeting
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results
Nine Presentations to Highlight Programs Including rigosertib Phase 3 Trial at the ASH Annual Meeting
|
View HTML
|
Toggle Summary |
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
|
View HTML
|
Toggle Summary |
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
Results From Phase 1 Trial of Oral Rigosertib and Azacitidine Combination Indicate Encouraging Rate of Response in MDS and AML
|
View HTML
|
Toggle Summary |
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
Detailed Data From Phase 3 ONTIME Trial Presented on Rigosertib Activity and Biological Plausibility in MDS Subgroups
|
View HTML
|
Toggle Summary |
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
|
View HTML
|